Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM
Rhythm Pharmaceuticals stock price today
$97.25
+41.66
+74.94%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Rhythm Pharmaceuticals stock price monthly change
+11.14%
month
Rhythm Pharmaceuticals stock price quarterly change
+11.14%
quarter
Rhythm Pharmaceuticals stock price yearly change
+11.99%
year
Rhythm Pharmaceuticals key metrics
Market Cap | 3.35B |
Enterprise value | 838.28M |
P/E | -5.28 |
EV/Sales | 35.46 |
EV/EBITDA | -4.81 |
Price/Sales | 40.83 |
Price/Book | 3.65 |
PEG ratio | 0.03 |
EPS | -4.63 |
Revenue | 91.92M |
EBITDA | -259.99M |
Income | -273.87M |
Revenue Q/Q | 126.41% |
Revenue Y/Y | 173.51% |
Profit margin | -766.22% |
Oper. margin | -757.92% |
Gross margin | 90.98% |
EBIT margin | -757.92% |
EBITDA margin | -282.83% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRhythm Pharmaceuticals stock price history
Rhythm Pharmaceuticals stock forecast
Rhythm Pharmaceuticals financial statements
Average Price Target
$63.4
Potential downside: -34.80%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 19.22M | -46.70M | -242.98% |
|---|---|---|---|
| Sep 2023 | 22.50M | -44.16M | -196.25% |
| Dec 2023 | 24.23M | -41.63M | -171.8% |
| Mar 2024 | 25.96M | -141.37M | -544.43% |
| Jun 2023 | 309943000 | 127.65M | 41.19% |
|---|---|---|---|
| Sep 2023 | 354199000 | 156.72M | 44.25% |
| Dec 2023 | 332745000 | 162.98M | 48.98% |
| Mar 2024 | 258651000 | 197.07M | 76.19% |
| Jun 2023 | -41.09M | 48.19M | -965K |
|---|---|---|---|
| Sep 2023 | -29.25M | -94.96M | 73.04M |
| Dec 2023 | -29.38M | 22.64M | 2.42M |
| Mar 2024 | -40.74M | 30.05M | 4.24M |
Rhythm Pharmaceuticals alternative data
| Aug 2023 | 177 |
|---|---|
| Sep 2023 | 177 |
| Oct 2023 | 177 |
| Nov 2023 | 177 |
| Dec 2023 | 177 |
| Jan 2024 | 177 |
| Feb 2024 | 177 |
| Mar 2024 | 226 |
| Apr 2024 | 226 |
| May 2024 | 226 |
| Jun 2024 | 226 |
| Jul 2024 | 226 |
Rhythm Pharmaceuticals other data
98.42%
+1.95%
of RYTM is owned by hedge funds
109
+15
48.81M
+381.43K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jul 2023 | 0 | 930 |
| Aug 2023 | 0 | 12941 |
| Sep 2023 | 0 | 6166 |
| Dec 2023 | 0 | 12941 |
| Feb 2024 | 0 | 92534 |
| Mar 2024 | 0 | 160024 |
| Apr 2024 | 0 | 368 |
| May 2024 | 0 | 3984 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | MATHERS EDWARD T director | Common Stock | 3,000 | N/A | N/A | ||
Option | MATHERS EDWARD T director | Restricted Stock Units | 3,000 | N/A | N/A | ||
Option | BEDROSIAN CAMILLE L director | Common Stock | 3,000 | N/A | N/A | ||
Option | ARBUCKLE STUART A director | Common Stock | 3,000 | N/A | N/A | ||
Option | ARBUCKLE STUART A director | Restricted Stock Units | 3,000 | N/A | N/A | ||
Option | MCGIRR DAVID W J director | Common Stock | 3,000 | N/A | N/A | ||
Option | MCGIRR DAVID W J director | Restricted Stock Units | 3,000 | N/A | N/A | ||
Option | TETRAULT LYNN A. director | Common Stock | 3,000 | N/A | N/A | ||
Option | TETRAULT LYNN A. director | Restricted Stock Units | 3,000 | N/A | N/A | ||
Option | BEDROSIAN CAMILLE L director | Restricted Stock Units | 3,000 | N/A | N/A |
| Patent |
|---|
Application Filling date: 4 Apr 2022 Issue date: 21 Jul 2022 |
Application Filling date: 13 Aug 2021 Issue date: 26 May 2022 |
Application Filling date: 9 Feb 2021 Issue date: 10 Jun 2021 |
Application Filling date: 5 Apr 2019 Issue date: 10 Jun 2021 |
Application Filling date: 15 Nov 2018 Issue date: 10 Jun 2021 |
Grant Filling date: 29 Sep 2016 Issue date: 30 Mar 2021 |
Grant Filling date: 15 Apr 2019 Issue date: 23 Mar 2021 |
Application Filling date: 13 Nov 2020 Issue date: 4 Mar 2021 |
Application Filling date: 26 Oct 2020 Issue date: 11 Feb 2021 |
Grant Utility: Peptide compositions Filling date: 11 Dec 2018 Issue date: 8 Dec 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 7 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 22 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 1 Aug 2023 | Q2 2023 Earnings Call Transcript |
Rhythm Pharmaceuticals: Rare Genetic Obesity Pioneer With Excellent Prospects
Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder
Rhythm Pharmaceuticals: A Virtual Monopoly In Orphan Obesity Disorders
Rhythm Pharma: An Incremental Approach Works Well For Setmelanotide
Rhythm Pharmaceuticals: Revisiting The Investment Thesis
Rhythm Pharmaceuticals: PDUFA Ahead, But Commercialization Concerns Remain
-
What's the price of Rhythm Pharmaceuticals stock today?
One share of Rhythm Pharmaceuticals stock can currently be purchased for approximately $97.25.
-
When is Rhythm Pharmaceuticals's next earnings date?
Unfortunately, Rhythm Pharmaceuticals's (RYTM) next earnings date is currently unknown.
-
Does Rhythm Pharmaceuticals pay dividends?
No, Rhythm Pharmaceuticals does not pay dividends.
-
How much money does Rhythm Pharmaceuticals make?
Rhythm Pharmaceuticals has a market capitalization of 3.35B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 227.56% to 77.43M US dollars.
-
What is Rhythm Pharmaceuticals's stock symbol?
Rhythm Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "RYTM".
-
What is Rhythm Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Rhythm Pharmaceuticals?
Shares of Rhythm Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Rhythm Pharmaceuticals have?
As Jul 2024, Rhythm Pharmaceuticals employs 226 workers.
-
When Rhythm Pharmaceuticals went public?
Rhythm Pharmaceuticals, Inc. is publicly traded company for more then 7 years since IPO on 9 Oct 2017.
-
What is Rhythm Pharmaceuticals's official website?
The official website for Rhythm Pharmaceuticals is rhythmtx.com.
-
Where are Rhythm Pharmaceuticals's headquarters?
Rhythm Pharmaceuticals is headquartered at 222 Berkeley Street, Boston, MA.
-
How can i contact Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals's mailing address is 222 Berkeley Street, Boston, MA and company can be reached via phone at 857 264 4280.
-
What is Rhythm Pharmaceuticals stock forecast & price target?
Based on 4 Wall Street analysts` predicted price targets for Rhythm Pharmaceuticals in the last 12 months, the avarage price target is $63.4. The average price target represents a -34.80% change from the last price of $97.25.
Rhythm Pharmaceuticals company profile:
Rhythm Pharmaceuticals, Inc.
rhythmtx.comExchange:
NASDAQ
Full time employees:
226
Industry:
Biotechnology
Sector:
Healthcare
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
222 Berkeley Street
Boston, MA 02116
Boston, MA 02116
CIK: 0001649904
ISIN: US76243J1051
CUSIP: 76243J105
